Pharmacokinetic (PK) assessment of BT1718: A phase I/II a study of BT1718, a first in class bicycle toxin conjugate (BTC), in patients (pts) with advanced solid tumours

N. Cook, U. Banerji, J. Evans, A. Biondo, T. Germetaki, M. Randhawa, L. Godfrey, S. Leslie, P. Jeffrey, M. Rigby, G. Bennett, S. Blakemore, M. Koehler, A. Niewiarowski, M. Pittman, S.N. Symeonides

Research output: Contribution to journalMeeting Abstractpeer-review

Original languageEnglish
Pages (from-to)v174
JournalAnnals of Oncology
Publication statusPublished - Oct 2019

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre

Cite this